Exploring antidiabetic drug targets as potential disease-modifying agents in osteoarthritis.

ABSTRACT:

Background

Osteoarthritis is a leading cause of disability, and disease-modifying osteoarthritis drugs (DMOADs) could represent a pivotal advancement in treatment. Identifying the potential of antidiabetic medications as DMOADs could impact patient care significantly.

Methods

We designed a comprehensive analysis pipeline involving two-sample Mendelian Randomization (MR) (genetic proxies for antidiabetic drug targets), summary-based MR (SMR) (for mRNA), and colocalisation (for drug-target genes) to assess their causal relationship with 12 osteoarthritis phenotypes. Summary statistics from the largest genome-wide association meta-analysis (GWAS) of osteoarthritis and gene expression data from the eQTLGen consortium were utilised.

Findings

Seven out of eight major types

SUBMITTER: Fu K 

PROVIDER: S-EPMC11378937 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature